Copy
The HIV&co-infections news bulletin delivers the latest news from the field of HIV/AIDS and co-infections.
HIV&CO-INFECTIONS NEWS BULLETIN
12/11/2018

Email not displayed correctly?
View it in your browser

Why U=U does not cover breastfeeding

11/11/2018
One of the last sessions at R4P2018 included six talks about U=U, one of which reviewed the evidence about breastfeeding. This is important because rather than just sexual transmission, U=U is sometimes wrongly interpreted as covering all ways that HIV can be transmitted. Lena Serghides from University Health Network and University of Toronto answered the ...
Read More ...

HIV Glasgow 2018: NATAP reports

11/11/2018
2018 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2018), 28-31 October 2018, Glasgow, UK NATAP reports: Waist-to-hip ratio predicts hepatic steatosis in people with HIV HIV linked to higher odds of anemia, neutropenia, and thrombocytopenia E-vaccine registry helps HIV group improve poor vaccination record SVR with DAAs–and darunavir–tied to lipid jumps in ...
Read More ...

Universal HCV screening on the way?

11/11/2018
Move afoot to recommend testing for everyone regardless of perceived risk Hepatitis C virus (HCV) is the most common bloodborne infection in the United States. In 2014, it killed more Americans than any other infectious disease. Rates of acute hepatitis C quadrupled from 2010 to 2016. Yet despite the high prevalence of HCV, the CDC estimates that about half ...
Read More ...

Universal screening for HCV superior to risk-based approach in pregnant women

11/11/2018
SAN FRANCISCO — Universal screening of pregnant women at risk for hepatitis C was more efficient and cost-effective compared with risk-based screening, according to data presented at The Liver Meeting 2018. “Our study was prompted by this combination of what was happening with the opioid epidemic and the very high number of young women testing ...
Read More ...

Health record prompts can improve hepatitis diagnosis

11/11/2018
DENVER — One in five people with HIV have never been tested for hepatitis C and two-thirds of gay and bisexual men with HIV have not been tested for hepatitis C in the past 12 months, new survey results from the Centers for Disease Control and Prevention (CDC) Medical Monitoring Project show. “One of the truly ...
Read More ...

Vaginal gel for HIV prevention so far ineffective in the real-world

11/11/2018
Young women in Africa are in desperate need of an HIV prevention method that is acceptable to them – but science has so far failed to provide. A vaginal gel designed to prevent HIV in women has been shown to be ineffective in a population of young women aged 18-30 in South Africa because of issues relating ...
Read More ...

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men

11/11/2018
Difference “equivalent to four days of PrEP per week rather than seven” A study presented at last month’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in their blood that are ...
Read More ...

Pharmacokinetics of lopinavir/ritonavir: Changes across formulations and ages

11/11/2018
Although dosing recommendations for lopinavir/ritonavir include larger doses for infants to account for higher apparent clearance, data demonstrate that this may still result in low lopinavir concentrations for infants younger than 6 months receiving the liquid formulation, according to a population pharmacokinetic analysis published in the Journal of Clinical Pharmacology.1 Lopinavir is recommended as part of ...
Read More ...

Nonalcoholic fatty liver disease may be underappreciated comorbidity among people with HIV

11/11/2018
Research on nonalcoholic fatty liver disease in persons infected with HIV revealed a prevalence of the condition of about 40%, suggesting the condition may be an underappreciated comorbidity in this population. A team of investigators led by Matthew Copeland, DO, an internist at Medstar Georgetown University Hospital in Washington, DC, set out to determine the ...
Read More ...

SOF/VEL/VOX successful for hepatitis C virus retreatment in patients with and without HIV

11/11/2018
A fixed-dose combination therapy of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX, Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence, according to results of a new study. Hepatitis C virus infection can ...
Read More ...

Gilead presents latest data from viral hepatitis research programs at The Liver Meeting® 2018

11/11/2018
Data demonstrate sofosbuvir-based regimens achieve high cure rates in hepatitis C patient populations with unmet need Early data from Gilead’s functional hepatitis B cure program suggest activation of immune cells crucial to viral clearance SAN FRANCISCO–Nov. 9, 2018– Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in chronic ...
Read More ...

AbbVie characterizes evolving hepatitis C patient landscape in the United States using comprehensive dataset

11/11/2018
New MappingHepC.com website provides HCV community an easily accessible source of chronic HCV epidemiology data NORTH CHICAGO, Ill., Nov. 9, 2018 — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from two studies that assessed HCV screening and diagnosis practices and linkage to care in the United States (US) at ...
Read More ...

Mavyret SVR high in patients with Sovaldi, NS5A inhibitor experience

11/11/2018
SAN FRANCISCO — Mavyret was highly effective and well-tolerated in patients with chronic hepatitis C genotype 1 who had experience with a combination of Sovaldi, NS5A inhibitor and ribavirin, according to data presented at The Liver Meeting 2018. “The context of this study was that the FDA granted approval in August 2017 for [Mavyret] for ...
Read More ...

ARO-HBV reduces all measurable viral products in patients with chronic hepatitis B virus infection

11/11/2018
The first results of a study on the use of monthly RNA interference (RNAi) with ARO-HBV (Arrowhead Pharmaceuticals) in patients with chronic hepatitis B virus infections indicate that the treatment effectively reduced “all measurable viral products, including HBsAg,” according to the study authors. Chronic hepatitis B virus infection affects about 16 million individuals in the ...
Read More ...

When is a nation’s HIV epidemic considered “controlled”?

08/11/2018
Despite many years of enthusiastic calls for an “end to AIDS,” experts have yet to settle on what that would actually entail. Read the full article by Benjamin Ryan in POZ here.  
Read More ...

November 2018 issue of The Lancet HIV now online

08/11/2018
The Lancet HIV is an exclusively online journal dedicated to publishing original research that advocates change in, or illuminates, HIV clinical practice. It publishes translational, epidemiological, clinical, operational, and implementation studies. The November 2018 issue is available here.  
Read More ...

Early HIV treatment reduces the risk of liver fibrosis

08/11/2018
Early antiretroviral therapy (ART) reduces the risk of liver fibrosis progression in people living with HIV, including in people who do not have co-infection with viral hepatitis, according to the results of the SMART study published in Hepatology. People with a high CD4 cell count (500 cells/mm3) who started immediate ART were about a third less ...
Read More ...

In utero HIV infection sharply increases cytomegalovirus risk for newborns

08/11/2018
Nearly 1 in 4 infants who acquire HIV infection in the womb will also contract congenital cytomegalovirus (CMV), according to new research. Kristina Adachi, MD, the study’s lead author and a clinical instructor in the division of infectious diseases at the University of California, Los Angeles, Department of Pediatrics, said previous research has linked HIV ...
Read More ...

HIV post-exposure prophylaxis often prescribed for anxiety, not need

08/11/2018
A retrospective review of HIV-1 post-exposure prophylaxis (PEP) finds it is often prescribed in response to patients’ emotional stress rather than according to treatment guidelines. Clara Lehmann, MD, Department of Internal Medicine, University of Cologne, Cologne, Germany, and colleagues acknowledged the difficulty in following treatment protocols in emotionally charged circumstances. “Decision making in PEP goes ...
Read More ...

Over 2 million Americans have hepatitis C; opioids help drive spread

08/11/2018
More than 2 million Americans have hepatitis C—and the opioid epidemic is a major contributor to the problem, according to a new government study. The study, by the U.S. Centers for Disease Control and Prevention, does highlight progress against the potentially fatal liver disease. It also shows how much more work remains, CDC officials said. ...
Read More ...

Jury still out on neural tube defects from dolutegravir

07/11/2018
GLASGOW — Ever since four infants with neural tube defects were born to women in Botswana who were using dolutegravir at conception, researchers and surveillance experts have been scrambling to see if their cohorts confirm or disprove the signal. Now, at HIV Drug Therapy 2018, four posters add to data from the Tsepamo surveillance cohort ...
Read More ...

PrEP sorting: HIV negative gay men prefer sexual partners who are using PrEP

07/11/2018
PrEP status is a significant factor for HIV negative men who have sex with men (MSM) when selecting sexual partners, but not when choosing friends or romantic partners for dating, according to an American study published in AIDS Care. The authors investigated whether use of pre-exposure prophylaxis (PrEP) influenced partner selection on an online dating ...
Read More ...

Novel antibiotic shows promise in treatment of uncomplicated gonorrhea

07/11/2018
An investigational oral antibiotic called zoliflodacin was well-tolerated and successfully cured most cases of uncomplicated gonorrhea when tested in a Phase 2 multicenter clinical trial, according to findings published today in the New England Journal of Medicine. The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, sponsored ...
Read More ...

Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

07/11/2018
Over 60% of patients with one or two drugs left achieve undetectable viral load The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual classes. Despite the overall success of antiretrovirals (ARVs), there remain a minority of people who, ...
Read More ...

Depression and alcohol misuse lower odds of achieving viral suppression in HIV

07/11/2018
Symptoms of depression and heavy alcohol use interact to lower the chances of achieving virologic suppression in people with HIV; therefore, interventions that target both depression and alcohol misuse may benefit those who are at high risk for poor outcomes, according to a study published in AIDS and Behavior. Although people living with HIV (PLWHIV) ...
Read More ...

WHO guidelines address need for physical health management in severe mental illness

07/11/2018
WHO has released evidence-based guidelines for managing physical health conditions in adults with severe mental disorders, according to a press release. The guidelines include recommendations on healthy lifestyle behaviors (eg, healthier diet, more physical activity and tobacco cessation), psychosocial support and considering possible interactions between different medications prescribed for mental and physical health conditions. “The majority of ...
Read More ...

Aidspan publishes new issue of ‘Global Fund Observer’

07/11/2018
Aidspan: Global Fund Observer Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, published Issue 345 of the ‘Global Fund Observer.’ The newsletter includes pieces on various topics, including an article on the Global Fund Board approval of another $28 million in grants from the 2017-2019 allocations; an interview with ...
Read More ...

How has Glasgow responded to an outbreak of HIV among people who inject drugs?

07/11/2018
Intensive efforts to reach people who inject drugs who have acquired HIV in a recent transmission outbreak in the city have resulted in high levels of antiretroviral treatment and viral suppression in a predominantly homeless population, clinicians and nurse specialists from Glasgow’s Brownlee Centre for Infectious Diseases reported in a poster discussion session dedicated to ...
Read More ...

The EATG publishes its position paper on drugs policy

06/11/2018
Today, on the occasion of the joint meeting of the EU Civil Society Forum on HIV, Hepatitis and TB and the EU Civil Society Forum on Drugs, the European AIDS Treatment Group publishes its position on different aspects of the drug policy debate and approaches to delivering health-based policies. With this position paper, we aim ...
Read More ...

The EATG in the Civil Society Fora joint meetings (Brussels 6-8 November)

06/11/2018
From 6-8 November, the EATG will be actively engaged in developing joint advocacy, sharing with and learning from civil society partners across Europe within the EU Civil Society Forum  on Drugs,  EU Civil Society Forum on HIV, Hepatitis and TB, EU Think Tank, High level Groups on Drugs that will be taking place in Brussels. ...
Read More ...

Gammora does not cure HIV

06/11/2018
An Israeli biotech company has issued a misleading press release which has encouraged some media outlets to falsely suggest that a new drug, Gammora, may be able to cure HIV. Zion Medical report that their study enrolled nine patients in Uganda. For the first four weeks, patients received a new drug called Gamorra. “Most patients ...
Read More ...

Long-term study shows that HIV-2 is deadlier than previously thought

06/11/2018
A study published in The Lancet HIV shows that HIV-2 is more pathogenic than previously demonstrated. The new findings indicate that early treatment should be applied to all patients with HIV, not only to those with HIV-1. “The study is unique in that we have followed cohort of study participants frequently over a long period, which enabled ...
Read More ...

Vertical HCV transmission fundamentally different according to maternal coinfection status

06/11/2018
Maternal neutralizing antibody responses have a role in preventing vertical transmission of hepatitis C virus, but not among women coinfected with HIV, according to study findings published in The Journal of Infectious Diseases. The findings suggest that the mechanism for vertical transmission of HCV may be different between monoinfected women and coinfected women, said Hugo Soudeyns, PhD, professor and chair of the ...
Read More ...

PrEP is safe for pregnant women who want the HIV prevention drug, a new study finds

06/11/2018
Pre-exposure prophylaxis, or PrEP, is safe for pregnant women to use, according to new research presented at the HIV Research for Prevention (HIVR4P2018) conference in Madrid, Spain. According the study, which evaluated pregnant women and infants in Kenya, babies born to women who took PrEP were no more likely to be underweight, to be born ...
Read More ...

ART initiated pre-pregnancy lowers hospitalization due to infection in HIV-exposed infants

06/11/2018
Beginning antiretroviral therapy (ART) prior to becoming pregnant was associated with a reduced risk for hospitalization because of infection in infants exposed to HIV but seronegative for the virus, according to a study published in Clinical Infectious Diseases. The incidence of pediatric HIV infection has been markedly reduced by successful prevention of mother to child transmission, but it ...
Read More ...

How providers can address HIV, aging and polypharmacy

06/11/2018
By 2020, about 70% of people living with HIV will be over the age of 50, and as they age, they will inevitably be administered even more medications. Long-term survivors have taken a variety of different antiretrovirals for decades, to which have been added other drugs to control not only complications of HIV but also ...
Read More ...

Identifying patterns of comorbidities in people living with HIV

06/11/2018
For a physician treating patients with several comorbidities can be increasingly challenging, and for individuals living with HIV, comorbidities can have a significant impact on the overall health outcomes of these patients. In a new study published in Open Forum Infectious Diseases, a team of international investigators found that comorbidities in people living with HIV tend ...
Read More ...

Doravirine (Pifeltro) approved in Canada for HIV treatment

06/11/2018
— This new anti-HIV drug is approved for use in combination therapy — Doravirine is a highly effective NNRTI (‘non-nuke’) taken once daily — Clinical trials showed greater tolerance of doravirine than older drugs in its class In October 2018 Health Canada approved the use and sale of a new anti-HIV drug, doravirine, to be ...
Read More ...

Dolutegravir plus darunavir maintains viral suppression without NRTIs

06/11/2018
A dual antiretroviral regimen containing dolutegravir (Tivicay) and boosted darunavir (Prezista) maintains viral suppression in most people who switch from a suppressive three-drug regimen, according to an observational study presented at the recent IDWeek in San Francisco. However, two drugs may not be enough for those who wish to switch while their viral load is ...
Read More ...

US: HIV stigma among health care providers holds back prevention goals

06/11/2018
Healthcare providers’ stigma toward patients with HIV is holding back HIV prevention goals, a study from the US Centers for Disease Control and Prevention (CDC) suggests. “National HIV screening recommendations place healthcare providers at the helm in the fight against HIV,” Angelica Geter, DrPH, MPH, research fellow, CDC’s Division of HIV/AIDS Prevention told MD Magazine®. “However, ...
Read More ...

Reaching the men: who are the partners of the young women with HIV in South Africa?

06/11/2018
In the high-prevalence countries of southern Africa, young women under 25 bear the brunt of the epidemic, with continued high rates of HIV infection. So much so, that epidemiologists at the HIV Research for Prevention Conference (HIVR4P 2018) in Madrid were referring to them with another acronym to join MSM (men who have sex with ...
Read More ...
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics of interest to the HIV treatment activist community. The EATG is not responsible for their content. The articles posted in this digest do not necessarily reflect EATG views or opinions.

FAIR USE NOTICE
The digest may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit. Information in this digest was accurately quoted during its compilation.
Twitter
Facebook
Website
Copyright © 2018 European AIDS Treatment Group, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from our list

Email Marketing Powered by Mailchimp